XKRX
322510
Market cap70mUSD
Dec 05, Last price
4,135.00KRW
1D
-0.72%
1Q
-34.78%
IPO
-52.96%
Name
JLK Inc
Chart & Performance
P/E
—
P/S
72.96
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
1.43b
-42.65%
Net income
-13.45b
L+83.71%
CFO
-10.94b
L+71.43%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
JLK, Inc. provides diagnosis support to the patients with it AI-driven solutions in South Korea. The company offers AI medical and AI security solutions. Its AI platform provides the on-site/real-time service that is connected to various systems built in the hospital and enables the professional needs of physicians to diagnose diseases. The company provides medical management, medical treatment, and medical service in brain diseases, such as ischemic stroke, hemorrhagic stroke, brain aneurysm, and Alzheimer's disease; and in lung diseases, coronary artery disease, prostate cancer, and digital pathology. The company was formerly known as JLK INSPECTION Co.,Ltd. JLK, Inc. is headquartered in Cheongju, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY |
|---|---|---|
| 2024‑12 | 2023‑12 | |
| Income | ||
Revenues | ||
Cost of revenue | ||
Unusual Expense (Income) | ||
NOPBT | ||
NOPBT Margin | ||
Operating Taxes | ||
Tax Rate | ||
NOPAT | ||
Net income | ||
Dividends | ||
Dividend yield | ||
Proceeds from repurchase of equity | ||
BB yield | ||
| Debt | ||
Debt current | ||
Long-term debt | ||
Deferred revenue | ||
Other long-term liabilities | ||
Net debt | ||
| Cash flow | ||
Cash from operating activities | ||
CAPEX | ||
Cash from investing activities | ||
Cash from financing activities | ||
FCF | ||
| Balance | ||
Cash | ||
Long term investments | ||
Excess cash | ||
Stockholders' equity | ||
Invested Capital | ||
ROIC | ||
ROCE | ||
| EV | ||
Common stock shares outstanding | ||
Price | ||
Market cap | ||
EV | ||
EBITDA | ||
EV/EBITDA | ||
Interest | ||
Interest/NOPBT | ||